Concepedia

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann, Johann S. de Bono, Neal D. Shore, Kim N., Michael J. Crosby, Josep M. Piulats, Aude Fléchon, Xiao X. Wei,

The Lancet · 2024 · 258 citations · 39 references

DOIFull text

Open access

Concepts

References

39

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

, , +12

Integrative Clinical Genomics of Advanced Prostate Cancer

Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu et al. · Cell · 2015 · 3.6K citations · Full text

, , +14

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

, , +17

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.2K citations · Full text

, , +17

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Colin C. Pritchard, Joaquı́n Mateo, Michael F. Walsh et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text

, , +17